bencro wrote: Quattro74 ... I'm with you (and Longholder99??) on whether or not we need/can afford a new external CEO at this moment.
My guess is that it pretty much relies on the "
ability/credibility" (or call this how you want) that Dr. Mandel has to secure a financing. My take is that has it, as this settlement was clearly
not related to financing issues (the OSC was very clear on that).
On the other hand, the OSC
requires that an external CEO be named
within a year.
I've also read
ALL the OSC documents. Not sure many did (and this is a problem here, like always, when we try to exchange on the same minimum level of basic information).
There are other things that must also be done before a new external CEO is hired. It's clearly stated.
As for trying to guess where TLT will be in 6 months, 1 year, 3 years, etc ... that's everybody's guess, like in everything else. One could be right for the right reasons, one could be right for the wrong reasons or even wrong for the wrong reasons.
I've provided clear details demonstrated that not much can be changed, given the thin structure that TLT had, some basic logic behind the structure of TLT and where each division are now, in terms of degree of clinical stages and sub-stages.
Can we kick the receptionist out? Probably, has this has less consequences.
Can we get rid of the therapeutic division? I doubt, for the reasons explained. Up to others to demonstrate the pros or cons, in a realistic way. That's all.
______________
Quattro74 - (3/2/2018 4:17:08 PM) RE:RE:RE:RE:RE:RE:New CEO vs. status of company
I also think that a new ceo isn't needed right now, will the canadian regulators renew Dr. Mandel after a year? If he's doing a good job maybe. It might be that he wanted that year limit in there. Ben, I think the next indication might be lung as it can be applied topically, via inhaler?, so no large animal model prior to a human phase 1. The key duties for Dr. Mandel this year are financing and getting products to market. So a major focus on CLT-cancer for tlc-2000, redesign, getting to phase 2 nmibc, then accelerated approval.